{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:26:00Z","timestamp":1770290760878,"version":"3.49.0"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Some patients with ulcerative colitis (UC) require immunosuppressants as maintenance therapy.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To assess epidemiological, clinical and disease factors at diagnosis that predict immunosuppressant use in UC.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> All UC patients diagnosed between 1992 and 2005 and currently managed in the inflammatory bowel disease (IBD) clinic were included. Forty\u2010three patients who currently or previously received azathioprine (AZA) or mercaptopurine (MP) for UC were compared with 130 controls. Charts were reviewed and logistic regression analyses were applied to identify factors associated with AZA or MP use.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> In univariate model, seven factors at diagnosis correlated with AZA use: male gender [odds ratio (OR) 2.2]; left\u2010sided or extensive colitis or pancolitis (OR 8.7\u201314.1); systemic steroid use within the first 6\u2003months of diagnosis (OR 5.1); more than 10 bowel movements daily (OR 6.4); persistent or mostly blood in stool (OR 2.8); endoscopic proven moderate to severe disease (OR 7.2\u201312.0) and requirement of hospitalization (OR 2.7) on diagnosis. In multivariate model, the first three factors were shown to be statistically significant.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Male gender, initial presentation with severe and extensive disease clinically and endoscopically, requirement of hospitalization on diagnosis or systemic steroids within 6\u2003months of diagnosis are predictive factors for immunosuppressant use in UC.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2008.03772.x","type":"journal-article","created":{"date-parts":[[2008,10,10]],"date-time":"2008-10-10T21:52:41Z","timestamp":1223675561000},"page":"606-613","source":"Crossref","is-referenced-by-count":23,"title":["Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case\u2013control study"],"prefix":"10.1111","volume":"28","author":[{"given":"A.","family":"LAU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"CHANDE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"PONICH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C.","family":"GREGOR","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.4.4.299"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01295733"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.26279"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.40036.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.01.048"},{"key":"e_1_2_6_7_2","first-page":"CD004277","article-title":"Cyclosporine A for induction of remission in severe ulcerative colitis","volume":"1","author":"Shibolet O","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.003"},{"key":"e_1_2_6_10_2","first-page":"CD000478","article-title":"Azathioprine and 6\u2010mercaptopurine for maintenance of remission in ulcerative colitis","volume":"1","author":"Timmer A","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199707000-00007"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)90552-2"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01072336"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6844.20"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.11481.x"},{"key":"e_1_2_6_16_2","first-page":"14","article-title":"Role of azathioprine in severe ulcerative colitis: one\u2010year, placebo\u2010controlled, randomized trial","volume":"19","author":"Sood A","year":"2000","journal-title":"Indian J Gastroenterol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.068809"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00344-1"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70354-4"},{"key":"e_1_2_6_20_2","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"43","author":"Weinshilboum RM","year":"1980","journal-title":"Am J Hum Genet"},{"key":"e_1_2_6_21_2","volume-title":"Package Insert for Azathioprine\/6\u2010Mercaptopurine","year":"2005"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2005.03832.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5375.89"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-8-641"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000225339.91484.fc"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.015"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-006-0574-6"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.09.033"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199810000-00003"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.6.905"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1159\/000200339"},{"key":"e_1_2_6_32_2","first-page":"852","article-title":"Predictors and the rate of medical treatment failure in ulcerative colitis","volume":"88","author":"Chakravarty BJ","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s535-002-8129-2"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2003.12.017"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198702000-00013"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2004.03486.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00705.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01945.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005589428082"},{"key":"e_1_2_6_40_2","volume-title":"Remicade (Infliximab) Advisory","author":"Health Canada"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000035662"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.049460"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28703"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H219"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01297.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2008.03772.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2008.03772.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T15:15:55Z","timestamp":1697210155000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2008.03772.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,31]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1365-2036.2008.03772.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03772.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,31]]}}}